Northstar Asset Management LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 0.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 39,072 shares of the company’s stock after selling 100 shares during the period. Johnson & Johnson comprises about 2.1% of Northstar Asset Management LLC’s investment portfolio, making the stock its 12th biggest holding. Northstar Asset Management LLC’s holdings in Johnson & Johnson were worth $5,442,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Fisher Asset Management LLC lifted its position in shares of Johnson & Johnson by 0.7% in the fourth quarter. Fisher Asset Management LLC now owns 11,337,653 shares of the company’s stock valued at $1,463,124,000 after acquiring an additional 78,572 shares in the last quarter. Clearbridge Investments LLC lifted its position in shares of Johnson & Johnson by 0.5% in the first quarter. Clearbridge Investments LLC now owns 9,628,443 shares of the company’s stock valued at $1,345,960,000 after acquiring an additional 48,582 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Johnson & Johnson by 14.2% in the first quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock valued at $1,217,494,000 after acquiring an additional 1,079,751 shares in the last quarter. Thoroughbred Financial Services LLC lifted its position in shares of Johnson & Johnson by 14,147.0% in the second quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock valued at $401,425,000 after acquiring an additional 3,986,071 shares in the last quarter. Finally, Swedbank lifted its position in shares of Johnson & Johnson by 5.5% in the fourth quarter. Swedbank now owns 4,001,754 shares of the company’s stock valued at $509,303,000 after acquiring an additional 209,665 shares in the last quarter. 66.78% of the stock is owned by institutional investors.
Several equities analysts have recently commented on the company. Wells Fargo & Co boosted their price objective on Wingstop from $76.00 to $84.00 and gave the company an “outperform” rating in a research report on Monday, May 6th. Barclays boosted their price objective on from GBX 200 ($2.61) to GBX 210 ($2.74) and gave the company an “equal weight” rating in a research report on Friday, June 21st. Royal Bank of Canada boosted their target price on Johnson Service Group from GBX 180 ($2.35) to GBX 190 ($2.48) and gave the stock an “outperform” rating in a research report on Tuesday, July 16th. Zacks Investment Research downgraded Hallmark Financial Services from a “buy” rating to a “hold” rating in a research report on Thursday, July 18th. Finally, Morgan Stanley set a $60.00 target price on Berry Global Group and gave the stock a “hold” rating in a research report on Wednesday, April 17th. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Johnson & Johnson currently has a consensus rating of “Buy” and a consensus target price of $148.56.
JNJ opened at $132.08 on Wednesday. The company has a market capitalization of $347.10 billion, a PE ratio of 16.15, a price-to-earnings-growth ratio of 2.21 and a beta of 0.70. The company’s 50 day simple moving average is $137.32. Johnson & Johnson has a one year low of $121.00 and a one year high of $148.99. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.13 and a current ratio of 1.44.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.42 by $0.16. The firm had revenue of $20.56 billion for the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a return on equity of 38.57% and a net margin of 20.08%. The company’s quarterly revenue was down 1.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.10 earnings per share. As a group, sell-side analysts expect that Johnson & Johnson will post 8.6 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be paid a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, August 26th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.88%. Johnson & Johnson’s dividend payout ratio is 46.45%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: What is Call Option Volume?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.